CR7952A - Sistema terapeutico transdermico estable a los rayos uv - Google Patents

Sistema terapeutico transdermico estable a los rayos uv

Info

Publication number
CR7952A
CR7952A CR7952A CR7952A CR7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A CR 7952 A CR7952 A CR 7952A
Authority
CR
Costa Rica
Prior art keywords
rays
active substance
absorbing agent
therapeutic system
transdermal therapeutic
Prior art date
Application number
CR7952A
Other languages
English (en)
Inventor
Schumacher Jochen
Susse Manfred
Mletzko Stephan
Ingwersen Jan-Peter
Langguth Thomas
Schenk Dirk
Kaffl Hubert
Dittgen Michael
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03003888A external-priority patent/EP1449526A1/de
Priority claimed from EP03004061A external-priority patent/EP1452173A1/de
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR7952A publication Critical patent/CR7952A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Abstract

El invento se refiere a un nuevo sistema terapeutico transdermico estable a los rayos UV (TTS) que consiste en una capa de base, por lo menos una matriz que contiene sustancia activa y opcionalmente una pelicula despegable y ademas un agente absorbedor de rayos UV, donde entre la capa de base y la matriz que contiene sustancia activa, que se encuentra mas alejada de la superficie de la piel, se preve por lo menos una capa adhesiva que contiene agente absorbedor de rayos UV y entre la capa adhesiva que contiene el agente absorbedor de rayos UV y la matriz que contiene sustancia activa, que estÓ mas alejada de la superficie de la piel, se preve por lo menos una capa separadora que es impermeable a la sustancia activa e impermeable al agente absorbedor de rayos UV.
CR7952A 2003-02-21 2005-08-19 Sistema terapeutico transdermico estable a los rayos uv CR7952A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03003888A EP1449526A1 (de) 2003-02-21 2003-02-21 UV-stabiles transdermales Pflaster
EP03004061A EP1452173A1 (de) 2003-02-25 2003-02-25 UV-stabiles transdermales Pflaster

Publications (1)

Publication Number Publication Date
CR7952A true CR7952A (es) 2006-02-06

Family

ID=32910125

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7952A CR7952A (es) 2003-02-21 2005-08-19 Sistema terapeutico transdermico estable a los rayos uv

Country Status (31)

Country Link
US (3) US8486443B2 (es)
EP (1) EP1594483B1 (es)
JP (1) JP4528296B2 (es)
KR (1) KR100704825B1 (es)
AR (1) AR043248A1 (es)
AT (1) ATE333271T1 (es)
AU (1) AU2004212675B2 (es)
BR (1) BRPI0407615B8 (es)
CA (1) CA2515918C (es)
CR (1) CR7952A (es)
CY (1) CY1105716T1 (es)
DE (1) DE502004000988D1 (es)
DK (1) DK1594483T3 (es)
EA (1) EA008098B1 (es)
EC (1) ECSP056030A (es)
ES (1) ES2270345T3 (es)
HK (1) HK1085394A1 (es)
HR (1) HRP20050828B1 (es)
IL (1) IL170295A (es)
IS (1) IS2541B (es)
ME (2) MEP14008A (es)
MX (1) MXPA05008778A (es)
NO (1) NO336108B1 (es)
NZ (1) NZ541807A (es)
PE (1) PE20041028A1 (es)
PL (1) PL219030B1 (es)
PT (1) PT1594483E (es)
RS (1) RS50428B (es)
SI (1) SI1594483T1 (es)
UY (1) UY28189A1 (es)
WO (1) WO2004073696A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407615B8 (pt) 2003-02-21 2021-05-25 Bayer Ip Gmbh sistema terapêutico transdérmico estável à radiação ultravioleta
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
CA2730498A1 (en) * 2008-07-14 2010-01-21 Surmodics, Inc. Medical devices and methods for delivery of nucleic acids
LT2613772T (lt) 2010-09-06 2017-03-27 Bayer Intellectual Property Gmbh Mažos dozės transderminiai pleistrai, pasižymintys aktyviu vaisto atpalaidavimu
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3936133A1 (en) 2011-11-23 2022-01-12 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10835499B2 (en) 2015-12-30 2020-11-17 Corium, Inc. Systems and methods for long term transdermal administration
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
DE102020104907A1 (de) * 2020-02-25 2021-08-26 Berliner Glas GmbH Verfahren zur Herstellung eines Bauelements durch atomares Diffusionsbonden

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939827A (ja) 1982-08-27 1984-03-05 Nitto Electric Ind Co Ltd 医療用外用部材
JPS6069014A (ja) 1983-09-27 1985-04-19 Nitto Electric Ind Co Ltd 皮膚疾患治療用貼付剤
US4573996A (en) * 1984-01-03 1986-03-04 Jonergin, Inc. Device for the administration of an active agent to the skin or mucosa
JPS60166611A (ja) 1984-02-10 1985-08-29 Nitto Electric Ind Co Ltd 疾患治療用部材
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5023084A (en) * 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
CH674618A5 (es) 1987-04-02 1990-06-29 Ciba Geigy Ag
US5538736A (en) * 1987-04-28 1996-07-23 Lts Lohmann Therapie-Systeme Gmbh Active substance-containing plaster for the controlled administration of active substances to the skin
US5128284A (en) * 1987-10-23 1992-07-07 Allied-Signal Inc. Preparation of lanthanum chromite powders by sol-gel
DE58909570D1 (de) * 1988-10-27 1996-02-22 Schering Ag Mittel zur transdermalen applikation enthaltend gestoden
EP0453396B1 (de) 1990-03-30 1995-12-13 Ciba SC Holding AG Lackzusammensetzungen
CA2066249C (en) * 1990-05-17 1997-12-16 Akira Nakagawa Estradiol percutaneous administration preparations
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
JPH06502419A (ja) 1990-10-29 1994-03-17 アルザ・コーポレーション 経皮避妊製剤、方法及びデバイス
JP3112707B2 (ja) 1991-07-25 2000-11-27 日本電気株式会社 監視システム用ポーリング方式
DE4336557C2 (de) * 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4336299A1 (de) * 1993-10-25 1995-05-11 Arbo Robotron Medizin Technolo Gelkörper zur percutanen Verabreichung, insbesondere von Medikamenten
DE4403487C2 (de) 1994-02-04 2003-10-16 Lohmann Therapie Syst Lts Arznei-Pflaster mit UV-vernetzbaren Acrylat-Copolymeren
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
WO1996015776A1 (fr) 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Timbre absorbable par voie percutanee
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟-麦内尔制药公司 基质层含有17-脱乙酰基诺孕酯的经皮贴片及基质的用途
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
JP3626275B2 (ja) 1996-04-09 2005-03-02 Jsr株式会社 光硬化性樹脂組成物
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
JP4346696B2 (ja) 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP3434135B2 (ja) 1996-07-11 2003-08-04 アルパイン株式会社 ナビゲーション装置
DE19701949A1 (de) * 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
JPH10265371A (ja) * 1997-03-25 1998-10-06 Sekisui Chem Co Ltd 経皮吸収貼付剤
AU723018B2 (en) 1997-04-16 2000-08-17 Hisamitsu Pharmaceutical Co., Inc. Base composition for percutaneous absorption and percutaneously absorbable preparation containing the base composition
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
JP4399044B2 (ja) 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
AR022471A1 (es) 1999-02-02 2002-09-04 Ortho Mcneil Pharm Inc Metodo para la fabricacion de matrices transdermicas
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE19912623A1 (de) 1999-03-20 2000-09-28 Lohmann Therapie Syst Lts Verfahren zur Erhöhung der Stabilität bei Lagerung und/oder Anwendung lichtempfindlicher therapeutischer Systeme oder deren Bestandteile
US8173592B1 (en) 1999-03-31 2012-05-08 Zentaris Ivf Gmbh Method for a programmed controlled ovarian stimulation protocol
KR20010112479A (ko) 1999-07-01 2001-12-20 나까도미 히로다카 경피흡수 첩부제
DK1242012T3 (da) 1999-11-24 2010-04-26 Agile Therapeutics Inc Forbedret transdermalt præventionsmiddelafgivelsessystem og fremgangsmåde
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
CA2424579C (en) * 2000-03-17 2009-11-03 Hisamitsu Pharmaceuticals Co., Inc. Ultraviolet-screening patch
EP1293199A4 (en) * 2000-06-13 2004-12-22 Hisamitsu Pharmaceutical Co PLASTER
DE10053375C1 (de) 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
TWI287455B (en) * 2000-12-05 2007-10-01 Noven Pharma Crystallization inhibition of drugs in transdermal drug delivery systems and methods of use
CN1652797A (zh) 2002-03-11 2005-08-10 詹森药业有限公司 连续使用抑制硫酸酯酶的孕激素的避孕给药方案
US6872401B2 (en) 2002-03-28 2005-03-29 L'oreal Cosmetic/dermatological compositions comprising a tetrahydrocurcuminoid and an amide oil
US7470452B1 (en) * 2002-06-13 2008-12-30 E. I. Du Pont De Nemours & Company Process for multilayer coating of substrates
US7032980B2 (en) * 2002-06-27 2006-04-25 The Little Tikes Company Non-slip wheel for a child's toy
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
BRPI0407615B8 (pt) 2003-02-21 2021-05-25 Bayer Ip Gmbh sistema terapêutico transdérmico estável à radiação ultravioleta
EP1452173A1 (de) 2003-02-25 2004-09-01 Schering AG UV-stabiles transdermales Pflaster
US8524272B2 (en) * 2003-08-15 2013-09-03 Mylan Technologies, Inc. Transdermal patch incorporating active agent migration barrier layer
WO2005021229A2 (en) * 2003-08-25 2005-03-10 Bfs Diversified Products, Llc Method and apparatus to monitor the compressive strength of insulation boards
WO2005023878A1 (en) 2003-09-11 2005-03-17 Ciba Specialty Chemicals Holding Inc. Water based concentrated product forms of light stabilizers made by a heterophase polymerization technique
US20050129756A1 (en) 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
EA011160B1 (ru) 2003-12-12 2009-02-27 Шеринг Акциенгезельшафт Композиция для трансдермальной доставки гормонов без необходимости использования агентов, усиливающих проникновение, и ее применения
US8668925B2 (en) * 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
UA89766C2 (en) 2003-12-12 2010-03-10 Байер Шеринг Фарма Акциенгезельшафт Transdermal delivery system of gestodene
JP4504109B2 (ja) 2004-06-15 2010-07-14 株式会社新陽社 画像表示装置及び画素構成体
EP1719504A1 (de) 2005-05-02 2006-11-08 Schering AG Festes transdermales therapeutisches System mit UV-Absorber
US8962013B2 (en) * 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
WO2010042152A2 (en) 2008-10-06 2010-04-15 Mylan Technologies, Inc. Amorphous rotigotine transdermal system

Also Published As

Publication number Publication date
EA200501224A1 (ru) 2006-04-28
CA2515918C (en) 2010-11-16
ATE333271T1 (de) 2006-08-15
PL219030B1 (pl) 2015-03-31
IL170295A (en) 2010-05-31
SI1594483T1 (sl) 2006-12-31
ES2270345T3 (es) 2007-04-01
RS50428B (sr) 2009-12-31
UY28189A1 (es) 2004-04-30
US9095691B2 (en) 2015-08-04
WO2004073696A1 (de) 2004-09-02
HRP20050828B1 (hr) 2013-10-25
HK1085394A1 (en) 2006-08-25
DK1594483T3 (da) 2006-11-20
BRPI0407615A (pt) 2006-02-14
AR043248A1 (es) 2005-07-20
IS8031A (is) 2005-09-15
ME00147B (me) 2010-10-10
US20130226113A1 (en) 2013-08-29
AU2004212675B2 (en) 2006-06-01
BRPI0407615B8 (pt) 2021-05-25
PL378035A1 (pl) 2006-02-20
RS20050639A (en) 2007-09-21
NO20054321L (no) 2005-09-20
ECSP056030A (es) 2006-01-27
KR20050103499A (ko) 2005-10-31
PT1594483E (pt) 2006-12-29
IS2541B (is) 2009-09-15
JP2006518348A (ja) 2006-08-10
CY1105716T1 (el) 2010-12-22
BRPI0407615B1 (pt) 2018-02-14
JP4528296B2 (ja) 2010-08-18
US20150335658A1 (en) 2015-11-26
KR100704825B1 (ko) 2007-04-09
EA008098B1 (ru) 2007-02-27
DE502004000988D1 (de) 2006-08-31
CA2515918A1 (en) 2004-09-02
NO336108B1 (no) 2015-05-18
EP1594483B1 (de) 2006-07-19
PE20041028A1 (es) 2005-02-18
EP1594483A1 (de) 2005-11-16
MXPA05008778A (es) 2006-05-25
US20060251707A1 (en) 2006-11-09
AU2004212675A1 (en) 2004-09-02
NZ541807A (en) 2009-07-31
US8486443B2 (en) 2013-07-16
HRP20050828A2 (en) 2006-03-31
MEP14008A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
CR7952A (es) Sistema terapeutico transdermico estable a los rayos uv
ES2581985T3 (es) Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal
AR097045A2 (es) Sistema terapéutico transdérmico
CL2003002767A1 (es) Composicion oral que comprende una pelicula que contiene un material funcional, en un vehiculo, util para el cuidado oral.
BRPI0412975A (pt) espuma penetrante para uso farmacêutico
DE50112720D1 (de) Transdermales therapeutisches system mit hochdispersem siliziumdioxid
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
AR029227A1 (es) Estructura compuesta de una matriz adhesiva que contiene una o varias substancias activas;procedimiento para fabricar una estructura compuesta, uso de estructuras compuestas y apilamiento de dichas estructuras compuestas.
AR028525A1 (es) Sistema terapeutico transdermal para la administracion de lerisetron
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
ES2523663T3 (es) Sistema terapéutico transdérmico sólido con un agente absorbente de los rayos UV
SE0300960D0 (sv) Material for packaging purposes
PT92903A (pt) Sistema terapeutico superficial contendo uma substancia activa antineoplastica,particularmente 5-fluorouracilo
PA8490701A1 (es) Composiciones extruidas livianas que contiene un portador ceramico liviano extruible, metodos de uso de las mismas y procesos para su preparacion
CU23518A3 (es) Sistema terapéutico transdérmico estable a los rayos ultravioletas
BRPI0011135B8 (pt) sistema de ministração terapêutica transdérmica contendo agente neuroléptico
ES2188021T3 (es) Metodo para evitar el uso indebido de un sistema terapeutico percutaneo.
AR037405A1 (es) Sistema terapeutico transdermal para la administracion de 17alfa-estradiol
AR022956A1 (es) Sistema transdermal terapeutico y procedimiento para su fabricacion
GT200600469A (es) Dispositivos de administración transdermica de drogas que contienen drospirenona y metodos de administración de la misma.
CO5550461A2 (es) Tratamiento de enfermedad parasitaria
AR012169A1 (es) Un articulo absorbente
CR8612A (es) Formas de dosificacion y composiciones farmaceuticas